Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Lb Pharmaceuticals Q3 2026 Results: Net Loss of $59.1M, Loss Widens

LB Pharmaceuticals Inc. reported continued clinical development of its lead candidate, LB-102, for the treatment of schizophrenia. The company recorded a net loss for the quarter, typical for a clinical-stage biopharmaceutical firm, with research and development expenses remaining the primary driver of cash outflow.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Profit before tax-59.1-3.6
Net income-59.1-3.6
EPS (diluted, $ a share)$-1.79$-0.61

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: LBRX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Lb Pharmaceuticals Inc: key numbers

Share price
$42.99Close, Nov 16
Market cap
$1.39B
Shares outstanding
32.36MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Lb Pharmaceuticals Inc

All →
4:20 PM ET 8-K
Financial Results

Lb Pharmaceuticals Financial Results

LB Pharmaceuticals reported third quarter 2026 financial results, highlighting a cash position of $403.8 million following a $150 million private placement. The company remains on track for a Phase 3 topline data readout for its lead schizophrenia candidate, LB-102, in the first half of 2027.

“We recently strengthened our leadership team with the appointments of Dr. Susan Kozauer as Chief Medical Officer and Joe Miller as Chief Financial Officer, adding two highly accomplished executives whose expertise is directly aligned with our next phase of growth as we advance LB-102 across multiple neuropsychiatric indications and prepare for potential commercialization in schizophrenia.”

Heather Turner, Chief Executive Officer of LB Pharmaceuticals

“Our recent R&D Day highlighted why we believe LB-102 has the potential to become the branded antipsychotic of choice, based on a differentiated profile with the potential to balance efficacy, tolerability, and simplicity of use.”

Heather Turner, Chief Executive Officer of LB Pharmaceuticals
8:06 AM ET 8-K
Executive Compensation

Lb Pharmaceuticals Executive Compensation

LB Pharmaceuticals appointed Susan G. Kozauer, M.D. as Chief Medical Officer, effective September 14, 2026. Her compensation package includes a $515,000 base salary, a 40% target bonus, a $150,000 sign-on bonus, and an inducement grant of 200,000 stock options vesting over four years.

Counterparty
Susan G. Kozauer, M.D.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.